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Abstract We describe the clinical course of a recurrent case of congenital fibrosarcoma
diagnosed in a 9-mo-old boy with a history of hemimelia. Following complete surgical
resection of the primary tumor, the patient subsequently presented with bulky bilateral
pulmonary metastases 6 mo following surgery. Molecular characterization of the tumor
revealed the absence of the prototypical ETV6-NTRK3 translocation. However, tumor
characterization incorporating cytogenetic, array comparative genomic hybridization, and
RNA sequencing analyses, revealed a somatic t(2;15)(2p21;15q25) translocation resulting
in the novel fusion of EML4 with NTRK3. Cloning and expression of EML4-NTRK3 in
murine fibroblast NIH 3T3 cells revealed a potent tumorigenic phenotype as assessed in
vitro and in vivo. These results demonstrate that multiple fusion partners targeting
NTRK3 can contribute to the development of congenital fibrosarcoma.
INTRODUCTION
Congenital fibrosarcoma is a soft tissue sarcoma that presents in children under the age
of 1 yr and represents 5%–10% of sarcomas in this age group (Orbach et al. 2010).
Complete surgical resection of the primary tumor is the primary mode of treatment for con-
genital fibrosarcoma and results in overall survival rates of >90% (Orbach et al. 2010).
Metastatic disease has been described for cases of congenital fibrosarcoma but occurs rarely
(Bourgeois et al. 2000). In contrast to adult fibrosarcoma, use of systemic chemotherapy in
neoadjuvant and adjuvant settings is effective in controlling and curing disease (Orbach
et al. 2010).
Diagnosis of congenital fibrosarcoma is made based on histologic appearance, consist-
ing of short spindle cells arranged in a fascicular growth pattern (herringbone pattern)
(Gupta et al. 2004). Congenital fibrosarcoma classically has positive staining for vimentin
but is negative for other lineage markers (pancytokeratin, EMA, desmin, HHF35, SMA, myo-
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are characterized by the ETV6-NTRK3 translocation (Knezevich et al. 1998b; Bourgeois et al.
2000), which has also been described in other neoplastic diseases such as mesoblastic ne-
phroma (Rubin et al. 1998; Knezevich et al. 1998a) and secretory breast carcinoma
(Tognon et al. 2002). Fluorescence in situ hybridization (FISH) using break-apart probes to
detect a translocation of the ETV6 and/or NTRK3 genes is routinely used to confirm diagno-
sis of congenital fibrosarcoma (Bourgeois et al. 2000). We describe a case of congenital
fibrosarcoma harboring a novel chromosomal translocation of NTRK3.
RESULTS
Clinical Presentation and Family History
A 9-mo-old male patient with a history of left upper extremity hemimelia presented with a
left distal radial lytic soft tissue mass (Fig. 1A,B). The child was the result of an uncompli-
cated pregnancy, and aside from the hemimelia, there were no other congenital anoma-
lies. There was no history of significant prenatal exposures, and the family history was
unremarkable.
Biopsy of the soft tissue mass suggested a diagnosis of congenital fibrosarcoma based
on histologic appearance (Fig. 1F) and positive staining for vimentin alone. The index
case exhibited a high mitotic index with up to 50 mitoses per 10 high power fields
(Fig. 1H). Cytogenetic analysis of the biopsied tumor revealed a complex karyotype con-
sisting of chromosomal gains and a translocation localized to t(2;15)(p21;q24) (Fig. 1C).
However, FISH analysis using an ETV6 break-apart probe showed no evidence of rearrange-
ment (Fig. 1D) indicating the absence of the characteristic ETV6-NTRK3 fusion gene associ-
ated with congenital fibrosarcoma (Knezevich et al. 1998b).
The patient underwent a surgical amputation resulting in a complete resection of the tu-
mor with negativemargins. Postoperative surveillance imaging 6mo after resection revealed
multiple bilateral lung metastases (Fig. 1E). Three days after imaging, the patient clinically
decompensated and was admitted to the Pediatric Intensive Care Unit where a biopsy of
his pulmonary lesions confirmed a diagnosis of relapsed congenital fibrosarcoma with histo-
logic features identical to his initial presentation (Fig. 1F).
The patient was treated as per the Children’s Oncology Group (COG) protocol
ARST0332 (NCT00346164) consisting of several cycles of ifosfamide and doxorubicin. In ad-
dition, he received targeted radiation therapy to his right lung metastasis to a total dose of
5000 cGy. All sites of disease responded to therapy as assessed by computed tomography
(CT) imaging, but positron emission tomography (PET)-CT imaging revealed mild residual
avidity in his left lung lesions. The patient underwent complete resection of the left-sided
PET avid lesions, which revealed small foci of viable tumor (Fig. 1G). Given the presence
of residual tumor, the patient received further systemic chemotherapy consisting of four cy-
cles of topotecan and cyclophosphamide (Saylors et al. 1998). Upon completion of systemic
chemotherapy, the patient underwent surgical resection of his residual right-sided lesions,
which revealed no evidence of viable tumor. The patient is clinically well and remains free
of disease more than 1 yr after completion of therapy.
Genomic Analyses
Because of the patient’s uncharacteristically aggressive clinical course and in the absence of
the prototypical ETV6-NTRK3 translocation, the histological diagnosis of congenital fibrosar-
comawas in question. Tomore comprehensively characterize themolecular basis of disease,
the patient was enrolled onto a multicenter targeted gene sequencing research study
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(Individualized Cancer Therapy [iCAT] Recommendation for Patients With Recurrent,
Refractory or High Risk Solid Tumors; NCT01853345) (Janeway et al. 2014) and underwent
full transcriptome sequencing in the Precision in Pediatric Sequencing (PIPseq) program at
Columbia University Medical Center. Transcriptome analysis was performed on two tumor
blocks, both of which consisted primarily of tumor with >60% lesional cells.
Figure 1. (A) Image of patient with left upper extremity hemimelia and distal arm soft tissue mass. (B) MRI im-
aging further demonstrates a 3.7 × 6 × 4.9-cm soft tissue mass within the distal left forearm. (C ) Karyotype de-
rived from tissue of the initial forearm lesion shows a complex karyotype: 52, XY, +2 t(2;15)(p21;q24), +8, +15,
+der(15)t(2;15)(p21;q24), +17, +19, −1D. White arrows indicate gains in Chromosomes 2, 8, 17, and 19. Black
arrows show a balanced t(2;15)(p21;q24) translocation as well as an extra copy of der(15)t(2;15). (D) Dual-
colored FISH using ETV6 break-apart probe showed no evidence for rearrangement. (E) Coronal computed
tomography scan of the chest∼6-mo postresection/amputation of the primary distal arm soft tissuemass dem-
onstrating interval development of bilateral pulmonary metastases. (F ) Hematoxylin and eosin (H&E) staining
of the pretherapy forearm biopsy that shows a spindle cell neoplasm arranged in a fascicular pattern and
characteristic of congenital fibrosarcoma. (G) Post-therapy H&E of resected lung metastases showed large
areas of tumor necrosis. However, there remained persistent areas of viable tumor. Scale bar, 200 μm. (H)
Tissue from the index case exhibits a high mitotic index with up to 50 mitoses per 10 high power fields.
Yellow arrowheads indicate mitotic figures. Scale bar, 50 μm.
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Cytogenetics
Cytogenetic analysis identified a complex and hyperdiploid karyotype showing a balanced
translocation between bands 2p21 and 15q24 resulting in a t(2;15)(p21;q24), an extra copy
of der(15)t(2;15), gains of Chromosomes 2, 8, 15, 17, and 19 (Fig. 1C).
Array Comparative Genomic Hybridization
Array comparative genomic hybridization (aCGH) showed clear copy-number transitions
within EML4 and NTRK3, with no copy-number alteration near the ETV6 locus (Fig. 2B–D).
The 5′ end of EML4 and the 3′ end of NTRK3 showed copy-number gain relative to the
rest of Chromosome 2 and Chromosome 15, respectively, suggestive of a fusion between
these genes and consistent with the karyotype. The additional copies of Chromosomes 8,
17, and 19 noted by karyotype were also clearly visible on array, while the remainder of
the genome did not show significant changes (Fig. 2A).
RNA and Directed Sequencing
Sequencing of RNA isolated from formalin-fixed paraffin-embedded tumor material was
used to identify RNA sequences that spanned two disparate chromosomes and where the
coding frame was predicted to be maintained in the fusion transcript. The highest scoring
in-frame fusion was one spanning the EML4 gene on Chromosome 2p and NTRK3 on
Chromosome 15q (Fig. 2E,F). The genomic coordinates of the RNA fusion junction localize
to Chr2:42472827/Chr15:88576276. In addition, increased expression of NTRK3 exons
downstream from the fusion was seen on RNA expression data. Of note, EML4 is transcribed
from the Watson strand (+) while NTRK3 transcribes from the Crick strand (−).
The read count track for EML4 (Fig. 2E) andNTRK3 (Fig. 2F) displays the count of strand-
specific reads aligning to the respective genes. Read counts for opposing strands are neg-
ligible and are not displayed. As is common in RNA-seq data, there are reads aligning to in-
trons, as well as exons, demonstrating what is likely to be nascent transcription of unspliced
pre-mRNA. The exon RPKM (reads per kilobase per million mapped reads) track displays
RPKM calculated over each exon and where the library size normalization factor was taken
to be the number of reads aligning to exons only. The RPKM data exhibit robust expression
of NTRK3 exons downstream from the breakpoint compared with upstream. The splicing
and fusion of exon 2 in EML4 and exon 14 in NTRK3 was detected by the FusionMap algo-
rithm (Ge et al. 2011). As demonstrated in the NTRK3 track (Fig. 2F), the actual genomic lo-
cation of the fusion, and the beginning of transcription for NTRK3, appears to occur within
intron 13 ofNTRK3. There is no clear point after EML4 exon 2 where transcription diminishes
suggesting that a wild-type EML4 is also being transcribed from the second copy of EML4.
No other pathogenic sequence variants were otherwise identified in our RNA-seq
analysis.
Functional Analyses
Verification of EML4-NTRK3 in Patient Sample
Based on previously described gene fusion isoforms involving the EML4 and NTRK3 genes,
oligonucleotide primers were designed to encompass previously known breakpoint junc-
tions of EML4-ALK and ETV6-NTRK3 (Knezevich et al. 1998b; Bourgeois et al. 2000; Wai
et al. 2000; Soda et al. 2007; Choi et al. 2008; Shinmura et al. 2008; Heuckmann et al.
2012). Using primers complimentary to the sequence in exon 2 of EML4 and exon 14 of
NTRK3, reverse transcription followed by PCR (RT-PCR) from the patient’s left-sided pulmo-
nary lesions resulted in a product whose sequence verified the in-frame junction (Fig. 2G).
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Figure 2. (A–D) Array comparative genomic hybridization (aCGH) showing copy-number gains at EML4 and
NTRK3 with transitions at the breakpoints. Blue color represents copy-number gain and red color represents
copy-number loss. (A) Overview of chromosomes with genes EML4 (Chr2), ETV6 (Chr12), and NTRK3 (Chr15)
highlighted. (B) EML4 with a transition from high copy gain to low copy gain at intron 2. (C ) No copy alteration
at ETV6. (D) NTRK3 with a transition from high copy gain to low copy gain at intron 12. (E,F ) Transcriptional
readout of the fusion between EML4 and NTRK3 from RNA-seq performed on primary tumor tissue. The
GRCh37 track displays the Ensembl gene annotation using standard representations for exons, introns, and
untranslated regions. EML4 is transcribed from the Watson strand (left to right) while NTRK3 transcribes
from the Crick strand (right to left). RPKM data show robust expression of NTRK3 exons downstream from
the breakpoint in comparison to upstream. Red arrows indicate the two exons (exon 2 in EML4 and exon 14
in NTRK3) whose splicing was detected using the FusionMap algorithm. The actual genomic location of the
fusion localizes within intron 13 of NTRK3. No clear point after EML4 exon 2 where transcription diminishes
is observed suggesting that a wild-type EML4 is also being transcribed from the second EML4 gene copy.
(G) Sanger sequencing confirmation of the in-frame fusion of EML4 (exon 2) and NTRK3 (exon 14).
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Cloning and In Vitro Assessment of EML4-NTRK3
We utilized a RT-PCR approach to cloning the entire coding sequence of the EML4-NTRK3
fusion transcript using RNA isolated from primary pulmonary metastatic tissue. In silico anal-
ysis of the EML4-NTRK3 coding sequence (http://web.expasy.org/compute_pi/) predicts
expression of a ∼48 kDa protein. Examination of the NTRK3-encoding sequence reveals
that the truncation of NTRK3 results in the loss of its transmembrane localization domain
(http://atlasgeneticsoncology.org/ [Knezevich et al. 1998b]) and preservation of its protein
kinase domain. In silico evaluation of the EML4 portion identifies an amino-terminal basic
domain, a hydrophobic echinoderm microtubule-associated protein-like protein (HELP)
domain and WD repeats (Choi et al. 2008). The truncation of the EML4 portion in EML4-
NTRK3 results in preservation of exons 1–2 encoding only for part of the basic region which
is encoded by exons 1–6 (Fig. 3A,B; Choi et al. 2008).
Murine fibroblast NIH 3T3 cells were transduced with packaged lentivirus encoding
EML4-NTRK3 (Fig. 3C). The expression of the fusion transcript was verified by RT-PCR
with primers spanning the fusion breakpoint (Fig. 3D). The expression of protein was as-
sessed by immunoblot using an NTRK3-directed antibody, demonstrating a protein at the
predicted molecular weight (MW) of 48 kDa (Fig. 3E).
The ability of EML4-NTRK3 to induce anchorage-independent growth was assessed by
growth of cells in soft agar. Control NIH 3T3 cells transduced with empty vector yielded no
colony formation, whereas cells transduced to express EML4-NTRK3 resulted inmacroscopic
colony formation 21 d after inoculation of cells into soft agar suggesting the transformation
of NIH 3T3 cells (Fig. 4A).
In Vivo Tumorigenicity
To assess the in vivo effects of EML4-NTRK3 expression, NIH 3T3 cells stably expressing
EML4-NTRK3 (NIH 3T3EML4-NTRK3) were injected subcutaneously into the flanks of immuno-
deficient mice. After 18 d of growth, mice injected with NIH 3T3EML4-NTRK3 cells had devel-
oped tumors that were nearly 2000 mm3 in size necessitating euthanasia as per animal
protocol guidelines. In contrast, mice injected with NIH 3T3 cells infected with empty vector
showed no evidence of tumor formation (Fig. 4B). Furthermore, the histologic appearance of
EML4-NTRK3-expressing tumors recapitulated the spindle cell herringbone pattern charac-
teristic of congenital fibrosarcoma (Fig. 4C).
DISCUSSION
We present a case of recurrent congenital fibrosarcoma that was responsive to multimodal
therapy (chemoradiotherapy and surgery) despite the presence of extensive bilateral pulmo-
nary metastases. The case did not harbor the characteristic ETV6-NTRK3 fusion oncogene
previously described in congenital fibrosarcoma, but was found to express a novel fusion
gene involving EML4 andNTRK3. Sequence verification and cloning of the EML4-NTRK3 fu-
sion gene allowed for functional characterization of this fusion protein. We show that expres-
sion of EML4-NTRK3 in NIH 3T3 cells is sufficient for cellular transformation, similar to the
ETV6-NTRK3 fusion oncogene (Knezevich et al. 1998b).
EML4 has also been described as a fusion partner with ALK to generate the EML4-ALK
gene fusion, which has been shown to drive non-small-cell lung cancer carcinogenesis
(Soda et al. 2007; Choi et al. 2008). The EML4-ALK fusion protein leads to constitutively ac-
tivated tyrosine kinase activity (ALK) through autodimerization of the EML4 portion. There
are at least 15 known transcripts of EML4-ALK, each with varying breakpoints within EML4
(Maus et al. 2012). In contrast to the variation in the breakpoints within EML4, truncation
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of the ALK gene is generally conserved resulting in the carboxy-terminal fusion of ALK from
exon 20, and encompassing the entire protein kinase domain. Of note, EML4-NTRK3 has
also recently been identified in G111, a glioma cell line in an RNA sequencing initiative to
identify oncogenic fusions in a large panel of cell lines (Klijn et al. 2015).
Analysis of the EML4-NTRK3 sequence reveals similarity in functional motifs to the pre-
viously described ETV6-NTRK3 that characterizes a significant proportion of congenital
fibrosarcoma cases. The NTRK3 portion of EML4-NTRK3 maintains the entire kinase domain
Figure 3. (A) (Top) Schematic of EML4 domains: Basic region, HELP domain, WD40 repeating domain;
(Middle) EML4-NTRK3 predicted domains showing the contribution of the EML4 Basic region and the com-
plete protein tyrosine kinase domain (PTK) ofNTRK3. (Bottom)NTRK3 domains: Signal peptide (SS), extracel-
lular ligand binding domain (ECD-LB), transmembrane domain (TM), and protein kinase domain. (B) (Top)
Schematic of ETV6 domains: Helix–loop–helix domain (HLH), internal domain (ID), ETS domain; (middle)
ETV6-NTRK3 predicted domains which fuses the HLH and ID regions of ETV6 to the entire PTK of NTRK3 sim-
ilar to the EML4-NTRK3 fusion; (bottom) NTRK3 domains: signal peptide (SS), extracellular ligand binding
domain (ECD-LB), transmembrane domain, and protein tyrosine kinase domain. (C ) Schematic of lentiviral
expression vector used for the stable transduction of EML4-NTRK3. (D) RT-PCR confirmation of the EML4-
NTRK3 fusion in stably transduced NIH 3T3 cells (NIH 3T3EML4-NTRK3), mouse tumors derived after subcutane-
ous injection of NIH 3T3EML4-NTRK3 cells, and tumor tissue derived from the patient’s pulmonarymetastasis. No
EML4-NTRK3 amplification was observed in either parental NIH 3T3 or empty vector NIH 3T3 cells which
served as negative controls. (E) Immunoblot analysis confirming the expression of EML4-NTRK3 in stably trans-
duced NIH 3T3EML4-NTRK3 cells using a monoclonal anti-NTRK3 antibody (EPR17341, Abcam). Brain lysate
served as a positive control for the wild-type NTRK3 protein which migrates at ∼110 kDa in comparison to
the EML4-NTRK3 fusion protein (predicted MW 48 kDa). Protein lysate obtained from empty vector-trans-
duced NIH 3T3 cells served as a negative control and shows no detectable band. β-Actin (Sigma-Aldrich)
served as a loading control.
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of NTRK3, and, just as in ETV6-NTRK3, lacks the transmembrane localization domain. ETV6-
NTRK3 preserves the ETV6 contributing HLH domain resulting in HLH-mediated dimeri-
zation and ligand-independent activation of the NTRK3 kinase (Knezevich et al. 1998b;
Bourgeois et al. 2000). In contrast, EML4-NTRK3 preserves only a small portion of the
EML4 basic region and the protein kinase portion of NTRK3 in its entirety. It is therefore un-
clear at this time if EML4-NTRK3 activation behaves in a similar manner as ETV6-NTRK3.
The presence of hemimelia is a notable clinical feature described in this clinical case of
congenital fibrosarcoma. Several signaling pathways involved in regulating limb bud pat-
terning and outgrowth are also known to play key roles in oncogenesis including sonic
hedgehog (SHH), fibroblast growth factor (FGF), and Wnt signaling pathways (Zuniga et al.
2012). For example, DKK1 has been shown to transform progenitor mesenchymal stem cells
Figure 4. (A) Expression of EML4-NTRK3 in NIH 3T3 cells promotes anchorage-independent growth. Empty
vector (left) and EML4-NTRK3-expressing NIH 3T3 cells (NIH 3T3EML4-NTRK3, right) were grown in soft agar.
Macroscopic colony formation was observed in NIH 3T3EML4-NTRK3 cells in contrast to empty vector control
cells. Crystal violet staining was performed to visualize macroscopic colony formation. (B) Expression of
EML4-NTRK3 induces in vivo tumor formation in NOD scid γ (NSG) mice. Mice received subcutaneous flank
injections of either empty vector-transduced NIH 3T3 cells or NIH 3T3EML4-NTRK3 cells (1 million cells/mouse).
After 18 d following injection of cells, mice who received NIH 3T3EML4-NTRK3 cells (right) were euthanized in
accordance with animal protocol guidelines which mandated euthanasia of animals harboring large tumors
(>2000 mm3). In contrast, mice injected with empty vector-transduced cells yielded only residual Matrigel
plugs and no evidence of tumor (left). (C ) Mouse tumors derived from NIH 3T3EML4-NTRK3 cells recapitulates
the histology of congenital fibrosarcoma. The histology observed in the mouse tumor (right) demonstrates
the characteristic herringbone pattern of spindle cells that was also seen in the primary patient tumor (left).
Scale bar, 100 μm.
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into tumors resembling high grade sarcomas and has also been implicated in the develop-
ment of congenital limb truncation anomalies in a mouse model constitutively expressing
DKK1 under a mesodermal-specific promoter (Matushansky et al. 2007; Navarro et al.
2010; Gibault et al. 2011; Dela Cruz et al. 2012). However, it remains unclear whether seg-
mental somatic mosaicism for the EML4-NTRK3 fusion or other genes have contributed
to the development of both the soft tissue tumor and hemimelia. Assessment of different
normal tissues from the source patient for the EML4-NTRK3 fusion may clarify this issue.
Identificationof thenovelEML4-NTRK3 fusion in this recurrent caseof congenital fibrosar-
comawasenabled throughclinicalgenomicsefforts (e.g., PIPseqand iCAT) thatarebeginning
to be incorporated in the diagnostic workup and molecular characterization of patients’ can-
cers (Janeway et al. 2014). The identification of novel genes, as well as so-called “actionable
mutations,” through the sequencing of patient primary tumors will enable the rationalmatch-
ingofpotentiallyeffectiveagents thatwouldnothaveotherwisebeen identifiedbasedonclin-
ical features and presentation alone. To illustrate the potential clinical utility of sequencing
tumors in thecontextof this clinical case, the identificationof anovelNTRK3-containing fusion
gene provides a preclinical rationale for the incorporation of crizotinib to the treatment regi-
men in the event of recurrent disease for this patient (Taipale et al. 2013).
Although cases of congenital fibrosarcoma carry an overall favorable prognosis, identifi-
cation of older patients diagnosed with fibrosarcoma or patients with ETV6-NTRK3-negative
disease, may represent a population of high-risk patients whose tumors are driven by
novel genes such as EML4-NTRK3. It would be interesting to determine the prevalence of
EML4-NTRK3 in archival samples of ETV6-NTRK3-negative congenital fibrosarcoma and
other fibrosarcomas and to correlate EML4-NTRK3 status with clinical outcome. The positive
response to cytotoxic chemotherapy as well as radiotherapy in this clinical case may be of
clinical relevance to patients who are found to harbor the EML4-NTRK3 fusion gene partic-




G-band karyotype analysis was performed on metaphase preparations obtained from cells
grown in short-term culture of fresh tumor tissue using standard methods. Karyotype was
described according to the International System for Human Cytogenetic Nomenclature
(International Standing Committee on Human Cytogenetic Nomenclature et al. 2009).
FISH was performed on formalin-fixed paraffin-embedded tissue according to standard pro-
tocols using an ETV6 break-apart probe (Abbott Molecular, USA). Fluorescence signals were
captured after counterstaining with 4′,6-diamidino-2-phenylindole (DAPI) using the
Cytovision Imaging system attached to a Nikon Eclipse 600 microscope (Applied Imaging).
Array Comparative Genomic Hybridization
aCGH utilized Agilent SurePrint G3 CGH and SNP Cancer Microarray 4×180. Reference
DNA was Agilent reference DNA. aCGH was performed in CLIA certified laboratories at
Boston Children’s Hospital and Claritas Genomics.
RNA and Directed Sequencing
One paraffin block, each containing predominantly tumor, with at least 60% lesional tissue,
was chosen from the excisional biopsy and resection specimens of the primary tumor. RNA
was extracted using the Qiagen RNeasy Kit (Qiagen). Sequencing libraries were prepared
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using the Illumina TruSeq Stranded Total RNA Library Prep Kit. Pooled, indexed libraries
were sequenced on an Illumina HiSeq2000 (100 base, paired-end reads). Fifty-one million
reads were obtained from the excision biopsy specimen and 110 million reads from the re-
section specimen. Following base-calling and alignment with the Tuxedo Suite, rejected
reads were analyzed using FusionMap (Ge et al. 2011) with default parameters for RNA
and alignment to GRCh37.3. The output was filtered to include in-frame fusions, with at least
one rescued read and three unique seed reads, and exclude known, recurrent artifacts.
Cloning of EML4-NTRK3
Total RNA was isolated from primary tissue obtained following resection of residual tumor
using manufacturer’s instructions (Qiagen). First strand cDNA was then generated also ac-
cording to manufacturer’s instructions (Life Technologies). In order to validate the presence
of the EML4-NTRK3 fusion, oligonucleotide primers localized to exon 2 of EML4 and exon 14
of NTRK3 were designed using Primer-BLAST (http://www.ncbi.nlm.nih.gov/tools/primer-
blast) (EML4 forward primer: AGA TCG CCT GTC AGC TCT TG, NTRK3 reverse primer:
ACTCTCTGTAGTGAACTTCCGG). PCR cycling conditions were: 94°C for 2min, followed
by 32 cycles of 94°C for 30 sec, 55°C for 45 sec, 68°C for 1 min, and a final extension of 68°C
for 7 min using Platinum Blue PCR SuperMix (Life Technologies).
After confirmation of the EML4-NTRK3 fusion gene by RT-PCR, cloning primers were
designed to amplify the complete coding sequence of the EML4-NTRK3 gene fusion
using the aforementioned PCR cycling conditions (EML4 cloning forward primer: ATG
GAC GGT TTC GCC G, NTRK3 cloning reverse primer: CTA GCC AAG AAT GTC CAG
GTA GA). The amplified EML4-NTRK3 sequence was subcloned into a sequencing
vector using the Topo-TA system according to manufacturer’s recommendations (Life
Technologies), and the coding sequence verified by Sanger sequencing (Genewiz). After
confirmation of the EML4-NTRK3 coding sequence, the fusion gene was subcloned into
a plenti6.2/V5 lentiviral expression vector according to manufacturer’s instructions (Life
Technologies).
Expression of EML4-NTRK3
After subcloning and sequence confirmation of EML4-NTRK3 into the lentiviral expression
vector, the expression vector was transfected into the 293TN packaging cell line according
to manufacturer’s instructions (Invitrogen packaging system). Lentiviral packaging using
an empty vector control was also performed. Packaged virus was then harvested and
used to infect NIH 3T3 cells (ATCC) using Polybrene (10 μg/mL, EMD Millipore). After
two serial infections, cell culture medium was supplemented with blasticidin (5 μg/mL, Life
Technologies) to select for blasticidin-resistant, EML4-NTRK3-expressing clones.
Detection of EML4-NTRK3
NIH 3T3 cells expressing EML4-NTRK3 (NIH 3T3EML4-NTRK3), were harvested and the expres-
sion of EML4-NTRK3 was assessed by RT-PCR using breakpoint primers with the same PCR
conditions as above. Cells analyzed were parental NIH 3T3 cells, empty vector-transduced
NIH 3T3 cells, NIH 3T3EML4-NTRK3, and primary tumor tissue obtained from in vivo mouse
studies, and total RNA isolated from primary tumor derived from the case patient.
Immunoblot Analysis
Lysates of PBS-washed NIH 3T3 cells (both empty vector control and EML4-NTRK3 trans-
duced) were prepared using 500 μL lysis buffer (RIPA [Thermo Scientific]), protease inhibitor
cocktail (Thermo Scientific), 10 mM Na4P2O7, and 2 mM EDTA). The mixture was incubated
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on ice for 30 min, vortexing every 10 min. It was then centrifuged at 13,200 rpm for 10 min,
and the supernatant then collected and stored at −80°C. Using 4%–12% Bis–Tris Gels (Life
Technologies), 5 μg of protein (mixed 1:1 with Laemmli buffer, Sigma-Aldrich) was analyzed
and proteins subsequently transferred onto nitrocellulose iBlot Transfer Stacks (Thermo
Scientific) using iBlot Gel Transfer Device. The membranes were incubated with 5% milk
blocking solution for 45 min followed by an overnight incubation at 4°C using a carboxy ter-
minus anti-TrkC antibody (1:500 dilution, EPR17341, Abcam). The membranes were subse-
quently washed with PBS-Tween 20 (0.5%) and incubated for 1 h with anti-rabbit IgG
horseradish-peroxidase linked (1:5000 dilution, GE Healthcare UK) at room temperature.
Membranes were again washed with PBS-Tween 20 (0.5%) and proteins were visualized
with HyGlo Chemiluminescent solution (Denville Scientific).
Soft Agar Colony Formation Assay
The soft agar assay for colony formation was performed according to an established protocol
(Muller et al. 1993). Parental NIH 3T3 cells and NIH 3T3 cells stably transduced with EML4-
NTRK3, cultured in DMEM F12 media (Life Technologies) with 10% FBS, 1% non-essential
amino acids, and 1% penicillin/streptomycin, were plated in triplicate at a density of 5000
cells per well using a six-well plate format. The cells were suspended in soft agar (0.3%
media/agarose/cell mixture). The plates were photographed 21 d after plating and stained
with crystal violet (0.0025% crystal violet in 10% formalin buffer, Sigma-Aldrich).
Mouse Xenograft Modeling
Three sets of 3 NOD-SCID γ null (NSG) mice (Jackson Laboratory) were used, all 8 wk old,
and each set injected with either parental NIH 3T3 cells, empty vector NIH 3T3 cells, or
EML4-NTRK3 infectedNIH 3T3 cells, respectively.Onemillion cells were injected permouse
subcutaneously and tumor growth was measured weekly using calipers. Mice injected with
EML4-NTRK3 infected NIH 3T3 cells were euthanized as per animal protocol guidelines 18 d
post injection due to the rapid formation and size of subcutaneous tumors (∼2000 mm3).
ADDITIONAL INFORMATION
Ethics Statement
Informed and signed consent was obtained and archived for the research performed and
publication of the results. The patient was enrolled onto the multicenter targeted gene se-
quencing research study (Individualized Cancer Therapy [iCAT] Recommendation for
Patients With Recurrent, Refractory or High Risk Solid Tumors; NCT01853345) with approval
from the Columbia University Medical Center Institutional Review Board under protocol
AAAJ5811. The patient was also consented for clinical sequencing at Columbia University
Medical Center through the Precision in Pediatric Sequencing Program (PIPseq). Animal
studies described in this manuscript have been approved by the Columbia University
Medical Center Institutional Animal Care and Use Committee (IACUC) under protocol
AAAF5850.
Database Deposition and Access
Array comparative genomic hybridization data has been deposited in the Dryad Digital
Repository (http://datadryad.org/) and registered under doi:10.5061/dryad.521j5, and
RNA-seq data has been deposited in the NCBI Sequence Read Archive (SRA; http://www.
ncbi.nlm.nih.gov/sra) under accession number SRP062247.
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